Lasofoxifene

Lasofoxifene (CP-336156) is an orally active and selective estrogen receptor modulator (SERM) . Lasofoxifene exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene can be used for research of breast cancer and postmenopausal osteoporosis[1][2].

Product Specifications

CAS Number

[180916-16-9]

Product Name Alternative

CP-336156

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

Estrogen Receptor/ERR

Type

Reference compound

Related Pathways

Vitamin D Related/Nuclear Receptor

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/lasofoxifene.html

Purity

99.27

Solubility

DMSO : 9.09 mg/mL (ultrasonic; adjust pH to 4 with 1 M HCl)

Smiles

OC1=CC=C2[C@@H](C3=CC=C(OCCN4CCCC4)C=C3)[C@@H](C5=CC=CC=C5)CCC2=C1

Molecular Formula

C28H31NO2

Molecular Weight

413.55

Precautions

H302, H312, H332

References & Citations

[1]Lainé M, et al. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. Breast Cancer Res. 2021 May 12. 23 (1) :54. |[2]Andreano KJ, et al. The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor. Mol Cancer Ther. 2020 Jul. 19 (7) :1395-1405. |[3]Andersson A, et al. Selective oestrogen receptor modulators lasofoxifene and bazedoxifene inhibit joint inflammation and osteoporosis in ovariectomised mice with collagen-induced arthritis. Rheumatology (Oxford) . 2016 Mar;55 (3) :553-63.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

NPJ Breast Cancer. 2022 Dec 14;8 (1) :130.|NPJ Breast Cancer. 2025 Nov 12;11 (1) :125.|bioRxiv. 2024 Jun 2:2024.05.28.596307.|Gynecol Oncol. 2019 Jul;154 (1) :199-206.|Mol Cancer Ther. 2020 Jul;19 (7) :1395-1405.